C4 Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- C4 Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $33.55M.
- C4 Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2021-06-30 was $169.48M.
- C4 Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $57.67M.
- C4 Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $169.47M, a 11.36% decline from fiscal 2020.
- C4 Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $191.17M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $33.55M 10-Q · filed 2026-08-11 | |
| 2023-12-31 | $57.67M 10-K · filed 2024-02-22 | |
| 2021-12-31 | $169.47M 10-K · filed 2023-02-23 | |
| 2021-06-30 | $169.48M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $191.17M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |